Precigen's stock surged 5.16% in after-hours trading on Wednesday, following the release of the company's full-year 2025 financial results and positive business updates.

The biopharmaceutical company reported revenue of $9.7 million for the year, surpassing analyst expectations of $8.4 million. This increase was driven by the first commercial sales of its FDA-approved therapy, PAPZIMEOS, which generated $3.4 million in net product revenue in the fourth quarter. The loss per share widened to $1.37 from $0.47 a year earlier, influenced by non-cash accounting items.

Investors reacted positively to the significant commercial progress highlighted in the report. Management noted strong demand and building momentum for PAPZIMEOS in the first quarter of 2026, with patient hub enrollment surpassing 300. Additional catalysts include a permanent J-code for reimbursement effective April 1, 2026, and a Marketing Authorization Application under review in Europe. The company also stated its cash position is expected to fund operations to a cash flow break-even point.